• "Breakthrough Monoclonal Antibody for COVID-19: Is VYD2311 the Next Big Thing in Treatment? Powered by Avonetics.com"

  • Feb 5 2025
  • Durée: 11 min
  • Podcast

"Breakthrough Monoclonal Antibody for COVID-19: Is VYD2311 the Next Big Thing in Treatment? Powered by Avonetics.com"

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • VYD2311, a monoclonal antibody for COVID-19, is showing promising Phase 1/2 clinical trial results. With a potential half-life exceeding 139 days, it could serve as a long-lasting alternative to vaccination, especially for immunocompromised individuals. However, concerns about its temporary effects and high cost have sparked debates on its feasibility compared to treatments like Paxlovid. Could this antibody change the game for COVID-19 management? For advertising opportunities, visit Avonetics.com.
    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de "Breakthrough Monoclonal Antibody for COVID-19: Is VYD2311 the Next Big Thing in Treatment? Powered by Avonetics.com"

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.